Novartis

Novartis announces plans to build flagship manufacturing hub in North Carolina

Marks latest milestone in company’s previously announced $23 billion investment in US infrastructure ...
Novartis

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Entering a catalyst-rich period, Novartis expects 15+ potentially submission-enabling readouts over the next two years. With significant replacement power and a robust pipeline featuring 30+ potential ...
Novartis

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
Novartis

Product portfolio

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...
Novartis

Novartis Indonesia

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis

Novartis and the NFL Get Proactive About Health

Sports have a universal appeal that transcends boundaries. Each weekend, the National Football League (NFL) ignites millions of passionate fans from across the country, demonstrating the deep ...
Novartis

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
Novartis

Novartis completes acquisition of Tourmaline Bio

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Basel, October 26, 2025 – Novartis today announced that it has entered into an agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based, biopharmaceutical company focused on a ...
Novartis

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...